Dilaterol 25 microgr/ml oral syrup for horses

Main information

  • Trade name:
  • Dilaterol 25 microgr/ml oral syrup for horses
  • Pharmaceutical form:
  • Oral liquid
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Dilaterol 25 microgr/ml oral syrup for horses
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Clenbuterol
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0423/001
  • Authorization date:
  • 26-09-2012
  • EU code:
  • UK/V/0423/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

AN:01218/2011

Issued:March2013

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1.NAMEOFTHEVETERINARYMEDICINALPRODUCT

Dilaterol25micrograms/mlsyrupforhorses.(AT,BE,CZ,ES,HU,IE,IT,LU,PL,PT,

RO,SK,UK)

Dilaterolvet.25micrograms/mlsyrupforhorses.(FI,IS,NO,SE)

Dilaterolvet.(DK)

Dilaterol22micrograms/mlsyrupforhorses(FR)

2.QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance

Clenbuterolhydrochloride25micrograms

(correspondingto22microgramsclenbuterol)

Preservatives:

Methylparahydroxybenzoate(E218)2.02mg

Propylparahydroxybenzoate0.26mg

Forafulllistofexcipients,seesection6.1

3.PHARMACEUTICALFORM

Syrup

Clearcolourlesssyrup

4.CLINICALPARTICULARS

4.1Targetspecies

Horses

4.2Indicationsforuse,specifyingthetargetspecies

Treatmentofrespiratorydiseaseinhorseswhereitisconsideredthatairwayobstruction

duetobronchospasmand/oraccumulationofmucusisacontributingfactor,and

improvedmucociliaryclearanceisdesirable.Tobeusedaloneorasadjuvanttherapy.

AN:01218/2011

Issued:March2013

Page2of5

4.3Contraindications

Donotuseincasesofknownhypersensitivitytotheactivesubstanceoranyofthe

excipients.

Donotuseinhorseswithknowncardiacdisease.

Foruseduringpregnancyorlactationseesection4.7.

4.4Specialwarningsforeachtargetspecies

None

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Incasesaccompaniedbybacterialinfectiontheadministrationofantimicrobialagentsis

recommended.

Incaseofglaucomatheproductmustonlybeusedafteracarefulrisk-benefit

assessment.

Specialprecautionsshouldbetakenincaseofhalothaneanaesthesia,sincetheheart

functioncanshowincreasedsensitivitytocatecholamines.

Specialprecautionstobetakenbythepersonadministeringthemedicinal

producttoanimals

Thisproductcontainsclenbuterolhydrochloride,abeta-agonist.

Wearglovestoavoidskincontact.Incaseofaccidentalskincontact,washaffectedarea

thoroughly.Ifirritationoccurs/persistsseekmedicaladvice.Washhandsthoroughlyafter

usingtheproduct.

Takecaretoavoideyecontact.Inthecaseofaccidentaleyecontact,flushthoroughly

withcleanwaterandseekmedicaladvice.

Donoteat,drinkorsmokewhenusingthisproduct.Incaseofaccidentalingestion,seek

medicaladviceimmediatelyandshowthepackageleaflettothehealthcareprofessional.

Peoplewithknownhypersensitivitytoclenbuterolshouldavoidcontactwiththe

veterinarymedicinalproduct.

4.6Adversereactions(frequencyandseriousness)

Clenbuterolmaycausesideeffectssuchassweating(mainlyneckregion),muscle

tremor,tachycardia,slighthypotensionorrestlessness.Thesearetypicalfor  -agonists

andoccurrarely.

AN:01218/2011

Issued:March2013

Page3of5

4.7Useduringpregnancyorlactation

Ifusedduringpregnancy,treatmentmustbediscontinuedaminimumof4daysbefore

theexpectedtimeofdelivery,sinceuterinecontractionsmaybeabolishedorlabourmay

beprolongedunderitsinfluence.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

TheproductantagonisestheeffectsofprostaglandinF2-alphaandoxytocin.

Theproductisantagonisedby  -adrenergicblockingagents.

Donotadministerconcurrentlywithotherbeta-adrenergicagents.

Duringtheuseofbothlocalandgeneralanaestheticsonecannotexcludeafurther

vasculardilatationandfallofbloodpressure,particularlyifusedincombinationwith

atropine.

4.9Amountstobeadministeredandadministrationroute

Fororaluse.

Eachdepressionofthepumpdelivers4mlofproduct(0.100mgofclenbuterol

hydrochloride,equivalentto0.088mgclenbuterol).

Thepumpneedstobeprimedbeforethefirstuseonly.Primethepumpbypressing

twiceanddiscardtheretrievedsyrup.

Itisnotpossibletoextractallthecontentsusingthepumpprovided.

Administer4mloftheproductper125kgbodyweighttwicedaily.

Thisisequivalenttotwicedailyadministrationof0.8microgramsclenbuterol

hydrochlorideperkgbodyweight.

Thesyrupshouldbeaddedtothefeed.

Treatmentshouldcontinueforaslongasnecessary

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Dosagesofclenbuterolhydrochlorideupto4timesthetherapeuticdose(administered

orally)foraperiodof90dayscausedtransientsideeffectstypicalforbeta2-

adrenoceptoragonists(sweating,tachycardia,muscletremor),whichrequiredno

treatment.

Incaseofaccidentaloverdose,a  -blocker(suchaspropranolol)maybeusedas

antidote.

4.11Withdrawalperiod(s)

Meatandoffal –28days

Notauthorisedforuseinlactatinganimalsproducingmilkforhumanconsumption.

AN:01218/2011

Issued:March2013

Page4of5

5.PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:selectivebeta-2-adrenoreceptoragonists

ATCVetcode:QR03CC13

5.1Pharmacodynamicproperties

Theproductcontainsclenbuterolhydrochloride,whichisasympathomimeticamine

whichpreferentiallybindsto 

2adrenoreceptorsoncellmembranesofthebronchi.This

subsequentlyactivatestheenzymeadenylatecyclaseinsmoothmusclecells,thus

providingintensebronchodilatingpropertiesanddecreasingairwayresistancewith

minimumeffectonthecardiovascularsystem.Theproducthasbeenshowntoinhibit

histaminereleasefrommastcellsinthelungs,andenhancemucociliaryclearancein

horses

5.2Pharmacokineticparticulars

Afteroraladministrationinhorses,clenbuterolisreadilyabsorbedandmaximumplasma

concentrationsreachedwithin2hoursofdosing.Steadystateconcentrationsinplasma

arereachedafter3-5daystreatmentandrangefrom1.0 –2.2ng/ml.

Thesubstanceisrapidlydistributedintissuesandmetabolisedprimarilybytheliver.

Clenbuterolisthemainexcretoryproductandapproximately45%ofthedoseis

eliminatedunchangedintheurine.Thekidneysexcrete70 –91%ofthetotaldose,and

theremainderiseliminatedinthefaeces(6 –15%).

6.PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Methylparahydroxybenzoate(E218)

Propylparahydroxybenzoate

Carbomer974P

Sucrose

Macrogol400

Glycerol(85%)

Ethanol(96%)

Sodiumhydroxide

Water,purified

6.2Incompatibilities

Notknown.

AN:01218/2011

Issued:March2013

Page5of5

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelflifeafterfirstopeningtheimmediatepackaging:3months

6.4.Specialprecautionsforstorage

Donotstoreabove25°C.Protectfromlight.

6.5Natureandcompositionofimmediatepackaging

355mlHDPEbottlesealedwithanaluminium/PEheatsealandatransparentHDPE

cap.Theproductissuppliedinacartonboxwithamulti-componentmechanicalpump

dispensercapableofdelivering4mloftheproduct.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7.MARKETINGAUTHORISATIONHOLDER

LeVetBeheerB.V.

Wilgenweg7

3421TVOudewater

TheNetherlands

8.MARKETINGAUTHORISATIONNUMBER

Vm41821/4001

9.DATEOFFIRSTAUTHORISATION

March2013

10.DATEOFREVISIONOFTHETEXT

March2013

Approved 7/03/13

7-12-2018

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Laboratoire RivaInc. and Laboratoires Trianon Inc. are voluntarily recalling five over-the-counter strawberry-flavoured acetaminophen oral drops for infants. The products are labeled as Biomedic, Option, Personnelle, Selection, or Laboratoires Trianon Inc. The products are packaged in 24 mL bottles and are used for pain and fever relief. They are being recalled because the child-resistant safety cap may be defective. This recall is in addition to previous recalls of children’s acetaminophen syrups for th...

Health Canada

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

There are no news related to this product.